You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Elevance Health expects at least 12% adjusted EPS growth in 2027 from a 2026 baseline of at least $26.75. The outlook relies on health benefits margin recovery, broader adoption of Calon's pharmacy and clinical capabilities, and a connected operating model.
Elevance Health, Inc. reaffirmed full year 2026 shareholders’ earnings guidance of at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items; adjusted shareholders’ earnings remain at least $29.00 per diluted share.
Elevance Health registered an automatic shelf for future sales of senior and subordinated debt, preferred and common stock, depositary shares, warrants, rights, stock purchase contracts and units. Unless otherwise specified, net proceeds will be used for general corporate purposes.
Elevance Health reported shareholders’ net income of $1,365 for the three months ended September 30, 2026, up 14.8%, while nine-month net income fell 10.2% to $4,592; medical membership declined 1.1% to 44,882 thousand.
Elevance Health raised its 2026 adjusted diluted earnings per share guidance to at least $29 after third-quarter adjusted diluted earnings per share of $6.99, and expects at least 12 percent growth in 2027 from a baseline of at least $26.75.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELV
this stock
Elevance Health, Inc.
|
$92.84B | +22.6% | +12.5% | 18.3 | 2.1% |
|
UNH
Unitedhealth Group Inc
|
$365.09B | +23.4% | +11.8% | 23.3 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$114.32B | +12.6% | +7.8% | 10.4 | 1.4% |
|
CI
Cigna Group
|
$78.26B | +7.9% | +11.2% | 13.1 | 2.4% |
|
HUM
Humana Inc
|
$54.05B | +75.7% | +10.1% | 43.7 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Elevance Health expects at least 12% adjusted EPS growth in 2027 from a 2026 baseline of at least $26.75. The outlook relies on health benefits margin recovery, broader adoption of Calon's pharmacy and clinical capabilities, and a connected operating model.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELV | +1.0% | +0.3% | +10.8% | +2.3% | +22.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.6% | +1.5% | +10.3% | +2.5% | +12.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
